Amgen (AMGN) announced that it has inked an exclusive deal with Tokyo-based Daiichi Sankyo to commercialize nine biosimilars in Japan, including adalimumab, bevacizumab and trastuzumab. According to the terms of the agreement, Amgen will be responsible for development and manufacturing and Daiichi will manage regulatory submissions and handle distribution and commercialization while Amgen will have a limited rights to co-promote the products. Amgen will retain all distribution and commercialization rights outside of Japan. Financial terms are not disclosed.